Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03110549 · ClinicalTrials.gov registry record · Phase 1

Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers

A Phase 1 study, sponsored by TaiMed Biologics.

Terminated
Registry status
Phase 1
Development phase
9
Enrollment target

NCT03110549: Clinical Trial Phase 1 study, sponsored by TaiMed Biologics.

NCT03110549 is a Phase 1 study that was terminated before completion, run by TaiMed Biologics. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03110549, a Phase 1 study, was terminated before completion, sponsored by TaiMed Biologics.

TERMINATED
Registry status
Phase 1
Development phase
9 participants
Enrollment target

Study Summary

The study is a Phase 1, randomized, double-blinded, placebo-controlled, sequential single dose escalation safety, tolerability and pharmacokinetic study of subcutaneous and intramuscular TMB-607 administered to HIV-negative volunteers.

Primary Outcome

Measurements of concentrations of TMB-607 in plasma will be used to determine the concentration-time profile of subcutaneous and intramuscular TMB-607 in all participants. TMB-607 plasma concentrations will be measured by a central lab using high-performance liquid chromatography - mass (HPLC-MS) method validated for the measurement of TMB-607 in human plasma.

Interventions

  • DRUG Placebo
  • DRUG TMB-607

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2016-11-21
Est. Completion 2019-07-22
Phase Phase 1
TaiMed Biologics

9 total trials

Why NCT03110549 stopped before completion

NCT03110549 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT03110549 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03110549 about?

NCT03110549 is a clinical study titled "Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers". The study is a Phase 1, randomized, double-blinded, placebo-controlled, sequential single dose escalation safety, tolerability and pharmacokinetic study of subcutaneous and intramuscular TMB-607 administered to HIV-negative volunteers.

What is the current status of trial NCT03110549?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2016-11-21. Estimated completion is 2019-07-22.

What interventions are being tested in trial NCT03110549?

The interventions under investigation include: Placebo (DRUG), TMB-607 (DRUG).

Who is sponsoring clinical trial NCT03110549?

This trial is sponsored by TaiMed Biologics, which has 9 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03110549's enrollment target sits among peer trials

9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-07-11

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT02986048 · started 2016-11-22

    Proton Therapy Patient Registry

  • NCT02734537 · started 2016-11-23 · Phase 2

    Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

  • NCT06536452 · started 2016-11-18

    Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects

  • NCT02861573 · started 2016-11-17 · Phase 1

    Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Source: ClinicalTrials.gov NCT03110549, the US trial registry maintained by the National Library of Medicine. NCT03110549 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.